Cargando…

Booster dose after 10 years is recommended following 17DD-YF primary vaccination

A single vaccination of Yellow Fever vaccines is believed to confer life-long protection. In this study, results of vaccinees who received a single dose of 17DD-YF immunization followed over 10 y challenge this premise. YF-neutralizing antibodies, subsets of memory T and B cells as well as cytokine-...

Descripción completa

Detalles Bibliográficos
Autores principales: Campi-Azevedo, Ana Carolina, Costa-Pereira, Christiane, Antonelli, Lis R, Fonseca, Cristina T, Teixeira-Carvalho, Andréa, Villela-Rezende, Gabriela, Santos, Raiany A, Batista, Maurício A, Campos, Fernanda M, Pacheco-Porto, Luiza, Melo Júnior, Otoni A, Hossell, Débora MSH, Coelho-dos-Reis, Jordana G, Peruhype-Magalhães, Vanessa, Costa-Silva, Matheus F, de Oliveira, Jaquelline G, Farias, Roberto H, Noronha, Tatiana G, Lemos, Jandira A, von Doellinger, Vanessa dos R, Simões, Marisol, de Souza, Mirian M, Malaquias, Luiz C, Persi, Harold R, Pereira, Jorge M, Martins, José A, Dornelas-Ribeiro, Marcos, Vinhas, Aline de A, Alves, Tatiane R, Maia, Maria de L, Freire, Marcos da S, Martins, Reinaldo de M, Homma, Akira, Romano, Alessandro PM, Domingues, Carla M, Tauil, Pedro L, Vasconcelos, Pedro F, Rios, Maria, Caldas, Iramaya R, Camacho, Luiz A, Martins-Filho, Olindo Assis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5049740/
https://www.ncbi.nlm.nih.gov/pubmed/26360663
http://dx.doi.org/10.1080/21645515.2015.1082693
_version_ 1782457769811509248
author Campi-Azevedo, Ana Carolina
Costa-Pereira, Christiane
Antonelli, Lis R
Fonseca, Cristina T
Teixeira-Carvalho, Andréa
Villela-Rezende, Gabriela
Santos, Raiany A
Batista, Maurício A
Campos, Fernanda M
Pacheco-Porto, Luiza
Melo Júnior, Otoni A
Hossell, Débora MSH
Coelho-dos-Reis, Jordana G
Peruhype-Magalhães, Vanessa
Costa-Silva, Matheus F
de Oliveira, Jaquelline G
Farias, Roberto H
Noronha, Tatiana G
Lemos, Jandira A
von Doellinger, Vanessa dos R
Simões, Marisol
de Souza, Mirian M
Malaquias, Luiz C
Persi, Harold R
Pereira, Jorge M
Martins, José A
Dornelas-Ribeiro, Marcos
Vinhas, Aline de A
Alves, Tatiane R
Maia, Maria de L
Freire, Marcos da S
Martins, Reinaldo de M
Homma, Akira
Romano, Alessandro PM
Domingues, Carla M
Tauil, Pedro L
Vasconcelos, Pedro F
Rios, Maria
Caldas, Iramaya R
Camacho, Luiz A
Martins-Filho, Olindo Assis
author_facet Campi-Azevedo, Ana Carolina
Costa-Pereira, Christiane
Antonelli, Lis R
Fonseca, Cristina T
Teixeira-Carvalho, Andréa
Villela-Rezende, Gabriela
Santos, Raiany A
Batista, Maurício A
Campos, Fernanda M
Pacheco-Porto, Luiza
Melo Júnior, Otoni A
Hossell, Débora MSH
Coelho-dos-Reis, Jordana G
Peruhype-Magalhães, Vanessa
Costa-Silva, Matheus F
de Oliveira, Jaquelline G
Farias, Roberto H
Noronha, Tatiana G
Lemos, Jandira A
von Doellinger, Vanessa dos R
Simões, Marisol
de Souza, Mirian M
Malaquias, Luiz C
Persi, Harold R
Pereira, Jorge M
Martins, José A
Dornelas-Ribeiro, Marcos
Vinhas, Aline de A
Alves, Tatiane R
Maia, Maria de L
Freire, Marcos da S
Martins, Reinaldo de M
Homma, Akira
Romano, Alessandro PM
Domingues, Carla M
Tauil, Pedro L
Vasconcelos, Pedro F
Rios, Maria
Caldas, Iramaya R
Camacho, Luiz A
Martins-Filho, Olindo Assis
author_sort Campi-Azevedo, Ana Carolina
collection PubMed
description A single vaccination of Yellow Fever vaccines is believed to confer life-long protection. In this study, results of vaccinees who received a single dose of 17DD-YF immunization followed over 10 y challenge this premise. YF-neutralizing antibodies, subsets of memory T and B cells as well as cytokine-producing lymphocytes were evaluated in groups of adults before (NVday0) and after (PVday30-45, PVyear1-4, PVyear5-9, PVyear10-11, PVyear12-13) 17DD-YF primary vaccination. YF-neutralizing antibodies decrease significantly from PVyear1-4 to PVyear12-13 as compared to PVday30-45, and the seropositivity rates (PRNT≥2.9Log(10)mIU/mL) become critical (lower than 90%) beyond PVyear5-9. YF-specific memory phenotypes (effector T-cells and classical B-cells) significantly increase at PVday30-45 as compared to naïve baseline. Moreover, these phenotypes tend to decrease at PVyear10-11 as compared to PVday30-45. Decreasing levels of TNF-α(+) and IFN-γ(+) produced by CD4(+) and CD8(+) T-cells along with increasing levels of IL-10(+)CD4(+)T-cells were characteristic of anti-YF response over time. Systems biology profiling represented by hierarchic networks revealed that while the naïve baseline is characterized by independent micro-nets, primary vaccinees displayed an imbricate network with essential role of central and effector CD8(+) memory T-cell responses. Any putative limitations of this cross-sectional study will certainly be answered by the ongoing longitudinal population-based investigation. Overall, our data support the current Brazilian national immunization policy guidelines that recommend one booster dose 10 y after primary 17DD-YF vaccination.
format Online
Article
Text
id pubmed-5049740
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-50497402016-10-12 Booster dose after 10 years is recommended following 17DD-YF primary vaccination Campi-Azevedo, Ana Carolina Costa-Pereira, Christiane Antonelli, Lis R Fonseca, Cristina T Teixeira-Carvalho, Andréa Villela-Rezende, Gabriela Santos, Raiany A Batista, Maurício A Campos, Fernanda M Pacheco-Porto, Luiza Melo Júnior, Otoni A Hossell, Débora MSH Coelho-dos-Reis, Jordana G Peruhype-Magalhães, Vanessa Costa-Silva, Matheus F de Oliveira, Jaquelline G Farias, Roberto H Noronha, Tatiana G Lemos, Jandira A von Doellinger, Vanessa dos R Simões, Marisol de Souza, Mirian M Malaquias, Luiz C Persi, Harold R Pereira, Jorge M Martins, José A Dornelas-Ribeiro, Marcos Vinhas, Aline de A Alves, Tatiane R Maia, Maria de L Freire, Marcos da S Martins, Reinaldo de M Homma, Akira Romano, Alessandro PM Domingues, Carla M Tauil, Pedro L Vasconcelos, Pedro F Rios, Maria Caldas, Iramaya R Camacho, Luiz A Martins-Filho, Olindo Assis Hum Vaccin Immunother Research Papers A single vaccination of Yellow Fever vaccines is believed to confer life-long protection. In this study, results of vaccinees who received a single dose of 17DD-YF immunization followed over 10 y challenge this premise. YF-neutralizing antibodies, subsets of memory T and B cells as well as cytokine-producing lymphocytes were evaluated in groups of adults before (NVday0) and after (PVday30-45, PVyear1-4, PVyear5-9, PVyear10-11, PVyear12-13) 17DD-YF primary vaccination. YF-neutralizing antibodies decrease significantly from PVyear1-4 to PVyear12-13 as compared to PVday30-45, and the seropositivity rates (PRNT≥2.9Log(10)mIU/mL) become critical (lower than 90%) beyond PVyear5-9. YF-specific memory phenotypes (effector T-cells and classical B-cells) significantly increase at PVday30-45 as compared to naïve baseline. Moreover, these phenotypes tend to decrease at PVyear10-11 as compared to PVday30-45. Decreasing levels of TNF-α(+) and IFN-γ(+) produced by CD4(+) and CD8(+) T-cells along with increasing levels of IL-10(+)CD4(+)T-cells were characteristic of anti-YF response over time. Systems biology profiling represented by hierarchic networks revealed that while the naïve baseline is characterized by independent micro-nets, primary vaccinees displayed an imbricate network with essential role of central and effector CD8(+) memory T-cell responses. Any putative limitations of this cross-sectional study will certainly be answered by the ongoing longitudinal population-based investigation. Overall, our data support the current Brazilian national immunization policy guidelines that recommend one booster dose 10 y after primary 17DD-YF vaccination. Taylor & Francis 2015-09-11 /pmc/articles/PMC5049740/ /pubmed/26360663 http://dx.doi.org/10.1080/21645515.2015.1082693 Text en © 2016 The Author(s). Published with license by Taylor & Francis Group, LLC http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.
spellingShingle Research Papers
Campi-Azevedo, Ana Carolina
Costa-Pereira, Christiane
Antonelli, Lis R
Fonseca, Cristina T
Teixeira-Carvalho, Andréa
Villela-Rezende, Gabriela
Santos, Raiany A
Batista, Maurício A
Campos, Fernanda M
Pacheco-Porto, Luiza
Melo Júnior, Otoni A
Hossell, Débora MSH
Coelho-dos-Reis, Jordana G
Peruhype-Magalhães, Vanessa
Costa-Silva, Matheus F
de Oliveira, Jaquelline G
Farias, Roberto H
Noronha, Tatiana G
Lemos, Jandira A
von Doellinger, Vanessa dos R
Simões, Marisol
de Souza, Mirian M
Malaquias, Luiz C
Persi, Harold R
Pereira, Jorge M
Martins, José A
Dornelas-Ribeiro, Marcos
Vinhas, Aline de A
Alves, Tatiane R
Maia, Maria de L
Freire, Marcos da S
Martins, Reinaldo de M
Homma, Akira
Romano, Alessandro PM
Domingues, Carla M
Tauil, Pedro L
Vasconcelos, Pedro F
Rios, Maria
Caldas, Iramaya R
Camacho, Luiz A
Martins-Filho, Olindo Assis
Booster dose after 10 years is recommended following 17DD-YF primary vaccination
title Booster dose after 10 years is recommended following 17DD-YF primary vaccination
title_full Booster dose after 10 years is recommended following 17DD-YF primary vaccination
title_fullStr Booster dose after 10 years is recommended following 17DD-YF primary vaccination
title_full_unstemmed Booster dose after 10 years is recommended following 17DD-YF primary vaccination
title_short Booster dose after 10 years is recommended following 17DD-YF primary vaccination
title_sort booster dose after 10 years is recommended following 17dd-yf primary vaccination
topic Research Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5049740/
https://www.ncbi.nlm.nih.gov/pubmed/26360663
http://dx.doi.org/10.1080/21645515.2015.1082693
work_keys_str_mv AT campiazevedoanacarolina boosterdoseafter10yearsisrecommendedfollowing17ddyfprimaryvaccination
AT costapereirachristiane boosterdoseafter10yearsisrecommendedfollowing17ddyfprimaryvaccination
AT antonellilisr boosterdoseafter10yearsisrecommendedfollowing17ddyfprimaryvaccination
AT fonsecacristinat boosterdoseafter10yearsisrecommendedfollowing17ddyfprimaryvaccination
AT teixeiracarvalhoandrea boosterdoseafter10yearsisrecommendedfollowing17ddyfprimaryvaccination
AT villelarezendegabriela boosterdoseafter10yearsisrecommendedfollowing17ddyfprimaryvaccination
AT santosraianya boosterdoseafter10yearsisrecommendedfollowing17ddyfprimaryvaccination
AT batistamauricioa boosterdoseafter10yearsisrecommendedfollowing17ddyfprimaryvaccination
AT camposfernandam boosterdoseafter10yearsisrecommendedfollowing17ddyfprimaryvaccination
AT pachecoportoluiza boosterdoseafter10yearsisrecommendedfollowing17ddyfprimaryvaccination
AT melojuniorotonia boosterdoseafter10yearsisrecommendedfollowing17ddyfprimaryvaccination
AT hosselldeboramsh boosterdoseafter10yearsisrecommendedfollowing17ddyfprimaryvaccination
AT coelhodosreisjordanag boosterdoseafter10yearsisrecommendedfollowing17ddyfprimaryvaccination
AT peruhypemagalhaesvanessa boosterdoseafter10yearsisrecommendedfollowing17ddyfprimaryvaccination
AT costasilvamatheusf boosterdoseafter10yearsisrecommendedfollowing17ddyfprimaryvaccination
AT deoliveirajaquellineg boosterdoseafter10yearsisrecommendedfollowing17ddyfprimaryvaccination
AT fariasrobertoh boosterdoseafter10yearsisrecommendedfollowing17ddyfprimaryvaccination
AT noronhatatianag boosterdoseafter10yearsisrecommendedfollowing17ddyfprimaryvaccination
AT lemosjandiraa boosterdoseafter10yearsisrecommendedfollowing17ddyfprimaryvaccination
AT vondoellingervanessadosr boosterdoseafter10yearsisrecommendedfollowing17ddyfprimaryvaccination
AT simoesmarisol boosterdoseafter10yearsisrecommendedfollowing17ddyfprimaryvaccination
AT desouzamirianm boosterdoseafter10yearsisrecommendedfollowing17ddyfprimaryvaccination
AT malaquiasluizc boosterdoseafter10yearsisrecommendedfollowing17ddyfprimaryvaccination
AT persiharoldr boosterdoseafter10yearsisrecommendedfollowing17ddyfprimaryvaccination
AT pereirajorgem boosterdoseafter10yearsisrecommendedfollowing17ddyfprimaryvaccination
AT martinsjosea boosterdoseafter10yearsisrecommendedfollowing17ddyfprimaryvaccination
AT dornelasribeiromarcos boosterdoseafter10yearsisrecommendedfollowing17ddyfprimaryvaccination
AT vinhasalinedea boosterdoseafter10yearsisrecommendedfollowing17ddyfprimaryvaccination
AT alvestatianer boosterdoseafter10yearsisrecommendedfollowing17ddyfprimaryvaccination
AT maiamariadel boosterdoseafter10yearsisrecommendedfollowing17ddyfprimaryvaccination
AT freiremarcosdas boosterdoseafter10yearsisrecommendedfollowing17ddyfprimaryvaccination
AT martinsreinaldodem boosterdoseafter10yearsisrecommendedfollowing17ddyfprimaryvaccination
AT hommaakira boosterdoseafter10yearsisrecommendedfollowing17ddyfprimaryvaccination
AT romanoalessandropm boosterdoseafter10yearsisrecommendedfollowing17ddyfprimaryvaccination
AT dominguescarlam boosterdoseafter10yearsisrecommendedfollowing17ddyfprimaryvaccination
AT tauilpedrol boosterdoseafter10yearsisrecommendedfollowing17ddyfprimaryvaccination
AT vasconcelospedrof boosterdoseafter10yearsisrecommendedfollowing17ddyfprimaryvaccination
AT riosmaria boosterdoseafter10yearsisrecommendedfollowing17ddyfprimaryvaccination
AT caldasiramayar boosterdoseafter10yearsisrecommendedfollowing17ddyfprimaryvaccination
AT camacholuiza boosterdoseafter10yearsisrecommendedfollowing17ddyfprimaryvaccination
AT martinsfilhoolindoassis boosterdoseafter10yearsisrecommendedfollowing17ddyfprimaryvaccination